Atara Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Atara Biotherapeutics

11/08/2025 21:50

Atara Biotherapeutics Inc ATRA.OQ reported quarterly adjusted earnings of 19 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.10.  The mean expectation of four analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -60 cents to -32 cents per share.

Revenue fell 38.6% to $17.58 million from a year ago; analysts expected $7.35 million.

Atara Biotherapeutics Inc's reported EPS for the quarter was 19 cents​.

The company reported quarterly net income of $2.39 million.

Atara Biotherapeutics Inc shares had risen by 41.9% this quarter and lost 17.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 66.7% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $17.00, about 35.6% above its last closing price of $10.96

This summary was machine generated from LSEG data August 11 at 08:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.46
0.19
Beat
Mar. 31 2025
-1.98
3.50
Beat
Dec. 31 2024
-3.58
-1.19
Beat
Sep. 30 2024
-1.93
-2.93
Missed